EURTAC Phase III study: Erlotinib nearly doubles progression-free survival vs. chemotherapy
In the first phase III study to include Western lung cancer patients, first-line treatment with erlotinib (Tarceva) nearly doubled progression-free survival compared with chemotherapy, according to research presented at the ...
Jul 5, 2011
0
0